HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 324 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 0.34 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $5,908 | +27.6% | 112,838 | -0.9% | 0.01% | +20.0% |
Q1 2024 | $4,630 | +10.4% | 113,820 | +0.4% | 0.01% | +11.1% |
Q4 2023 | $4,192 | -3.5% | 113,420 | -0.3% | 0.01% | -10.0% |
Q3 2023 | $4,344 | +5.3% | 113,720 | -0.5% | 0.01% | +11.1% |
Q2 2023 | $4,124 | -6.7% | 114,320 | -1.2% | 0.01% | -10.0% |
Q1 2023 | $4,418 | -33.6% | 115,681 | -1.1% | 0.01% | -37.5% |
Q4 2022 | $6,652 | -99.9% | 116,914 | +0.2% | 0.02% | +33.3% |
Q3 2022 | $4,616,000 | -10.6% | 116,736 | -0.5% | 0.01% | -7.7% |
Q2 2022 | $5,162,000 | +14.1% | 117,323 | +3.4% | 0.01% | +44.4% |
Q1 2022 | $4,526,000 | -0.6% | 113,486 | +0.2% | 0.01% | 0.0% |
Q4 2021 | $4,555,000 | +15.8% | 113,286 | +17.1% | 0.01% | +12.5% |
Q3 2021 | $3,935,000 | -0.6% | 96,728 | +10.9% | 0.01% | 0.0% |
Q2 2021 | $3,960,000 | +13.7% | 87,211 | +4.4% | 0.01% | +14.3% |
Q1 2021 | $3,483,000 | +2237.6% | 83,553 | +2287.2% | 0.01% | – |
Q4 2020 | $149,000 | – | 3,500 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Third Security, LLC | 14,092,771 | $206,177,000 | 28.12% |
BB BIOTECH AG | 8,322,860 | $121,763,000 | 3.90% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 398,633 | $4,579,000 | 2.84% |
DOHENY ASSET MANAGEMENT /CA | 227,193 | $3,324,000 | 2.43% |
SNYDER CAPITAL MANAGEMENT L P | 2,833,759 | $41,458,000 | 2.24% |
First Light Asset Management, LLC | 938,399 | $13,729,000 | 2.19% |
IRIDIAN ASSET MANAGEMENT LLC/CT | 9,027,164 | $132,067,000 | 1.77% |
Taylor Wealth Management Partners | 204,277 | $2,989,000 | 1.72% |
Sterling Global Strategies LLC | 22,000 | $321,860,000 | 1.63% |
Granite Investment Partners, LLC | 988,939 | $14,468,000 | 1.06% |